ALK and non-small cell lung carcinoma: Although the benefit of sequential ALK TKIs has yet to be confirmed in clinical trials, multiple real-world data studies, including this study, demonstrate the potential benefit of sequential ALK TKI treatments compared to only one line of ALK TKI treatment for patients with advanced ALK-positive NSCLC.